We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

A. Menarini Diagnostics S.r.l.

A. Menarini Diagnostics S.r.l. is fully committed to developing high tech diagnostics instruments and reagents to imp... read more Featured Products: More products

Download Mobile App




Novel Tweak Increases Ability of Liquid Biopsy to Detect Circulating Cancer Cells

By LabMedica International staff writers
Posted on 19 Jul 2022
Print article
Image: The CELLSEARCH System is the first and only clinically validated, FDA-cleared system for identification, isolation, and enumeration of circulating tumor cells (CTCs) from a simple blood test (Photo courtesy Menarini Silicon Biosystems Inc.)
Image: The CELLSEARCH System is the first and only clinically validated, FDA-cleared system for identification, isolation, and enumeration of circulating tumor cells (CTCs) from a simple blood test (Photo courtesy Menarini Silicon Biosystems Inc.)

The sensitivity of an automated system that isolates, photographs, and counts circulating tumor cells from liquid biopsy blood samples was increased by adding an anti- chaperonin antibody to the assay platform.

Chaperonins comprise a family of heat shock proteins that prevent misfolding of proteins during stressful situations such as high heat, by assisting protein folding. Chaperonins undergo large conformational changes during a folding reaction as a function of the enzymatic hydrolysis of ATP as well as binding of substrate proteins and co-chaperonins. These conformational changes allow the chaperonin to bind an unfolded or misfolded protein, encapsulate that protein within one of the cavities formed by the two rings, and release the protein back into solution. Upon release, the substrate protein will either be folded properly or will require further rounds of folding, in which case it can again be bound by a chaperonin.

Investigators at the University of Central Florida (Orlando, USA) had found previously that expression of the second subunit of Chaperonin-Containing TCP-1 (CCT2) was inversely correlated with cancer patient survival and was essential for tumor development, driving tumor-promoting processes such as proliferation and anchorage-independent growth. In the current study, the investigators used CCT2 as a marker to detect circulating tumor cells (CTCs) that were shed from tumors during their development.

For this study, the investigators worked with the Menarini Silicon Biosystems Inc. (Huntington Valley, PA, USA) CELLSEARCH System (CSS) detection platform. The CELLSEARCH System detects and enumerates CTCs of epithelial origin from a 7.5- milliliter blood sample with a high level of sensitivity and specificity. It provides rapid, precise, and reproducible analysis of CTCs with a simple three-step process: sample collection, sample preparation, and sample analysis using unique immunomagnetic and fluorescence imaging technology.

Since not all blood samples from cancer patients contain detectable CTCs, the investigators used the approach of spiking a known number of cancer cells into blood from healthy donors as the basis of a liquid biopsy approach using CCT2 to distinguish rare cancer cells from the large number of non-cancer cells in blood. The addition of an anti-CCT2 antibody to the CSS platform resulted in improved CTC image analysis and increased detection of rare breast cancer and small cell lung cancer (SCLC) cells spiked into blood, which was confirmed in a pilot study of blood from SCLC patients.

Results revealed that CCT2 protein levels were increased in tumor tissues compared to normal tissues and could be used as a marker for metastatic tissues. This finding suggested that detection of CCT2 could identify rare cancer cells in blood and could be used in liquid biopsy approaches to enhance the use of minimally invasive methods for cancer diagnosis.

Senior author Dr. Annette Khaled, head of the division of cancer research at the University of Central Florida, said, “The chaperonin complex is a significant indicator of a cancer’s severity and the more chaperonin complex, the more advanced the cancer. By using the chaperonin complex to detect cancer cells in blood, we get a warning that the cancer may be spreading. Using the chaperonin complex to detect cancer cells in blood is a unique solution for a non-invasive diagnosis.”

The chaperonin-based liquid biopsy technique was described in the June 24, 2022, online edition of the journal PLOS ONE.

Related Links:
University of Central Florida 
Menarini Silicon Biosystems Inc. 

 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.